Announcements Trials
Browse Landscape

Phase

Phase 2 42Phase 1 30Phase 1/2 22Phase 3 4Phase NA 3Phase EARLY_PHASE1 2Phase 2/3 2

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 3Classical hematology 1

Conditions

Breast Neoplasms 250Carcinoma, Non-Small-Cell Lung 226Prostatic Neoplasms 118Neoplasms 106Multiple Myeloma 91Neoplasm Metastasis 75Colorectal Neoplasms 73Parkinson Disease 4, Autosomal Dominant Lewy Body 69Lung Neoplasms 67Ovarian Neoplasms 61Leukemia, Myeloid, Acute 50Carcinoma, Hepatocellular 48Melanoma 47Carcinoma, Renal Cell 45Leukemia, Lymphocytic, Chronic, B-Cell 44Triple Negative Breast Neoplasms 42Urinary Bladder Neoplasms 41Stomach Neoplasms 41Squamous Cell Carcinoma of Head and Neck 41Recurrence 41Brain Neoplasms 40Myasthenia Gravis 37Small Cell Lung Carcinoma 35Nasopharyngeal Carcinoma 34Lymphoma, Follicular 34Head and Neck Neoplasms 34Pancreatic Neoplasms 32Rectal Neoplasms 31Lymphoma, Large B-Cell, Diffuse 30Endometrial Neoplasms 29

Interventions

Azacitidine 3sabatolimab 1pevonedistat 1Lenalidomide 1Epoetin Alfa 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, Myelomonocytic, Chronic × 1 year × Clear all
NCT00843882 2026-05-29

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
247 enrolled 19 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04266301 2026-01-13

STIMULUS-MDS2

Novartis

Phase 3 Terminated
530 enrolled 29 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT06647862 2025-11-25

IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Phase 3 Recruiting
170 enrolled
Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

NCT03268954 2025-10-29

PANTHER

Takeda

Phase 3 Completed
454 enrolled 41 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡